



Key Feature #1:

Zenalpha® contains 0.5 mg/mL medetomidine hydrochloride and 10 mg/mL vatinoxan hydrochloride.

- Medetomidine is an alpha-2 agonist responsible for sedative and analgesic properties.
- Vatinoxan is an alpha-2 antagonist, acting in the periphery without crossing the blood-brain barrier.

Its Benefit:

Combination of medetomidine and vatinoxan helps minimize unwanted cardiovascular side effects while preserving reliable sedation and analgesia. Zenalpha® improves the sedation monitoring experience by keeping the patient's heart rate and blood pressure closer to normal.

Zenalpha® is for use in dogs only. Not intended for use in cats.

Key Feature #2:

Zenalpha® offers a short time to onset (5-15 minutes) and a short duration of sedation (~45 minutes) in most dogs.*

*Field study means were 14 minutes for time to onset of sedation and 38 minutes for duration of sedation.

Its Benefit:

Patients recover rapidly and can return home sooner. And due to the quick recovery time, the use of reversal agents may not be needed, which can save time and decrease costs.

As with all alpha-2 adrenoceptor agonists, onset of sedation may be delayed or may be inadequate in some dogs. The analgesic effect of Zenalpha® will not last longer than the sedative effects. Additional analgesic(s) should be administered as needed.

Key Feature #3:

Zenalpha® is effective for a broad range of common clinical procedures including nail trims, diagnostic imaging, and end-of-life procedures.

Its Benefit:

Using procedural sedation with Zenalpha® is consistent with low-stress handling techniques and helps facilitate best practices. It may help reduce a patient's fear, anxiety, and stress, improve comfort, and minimize accidental injuries.

Due to the pronounced cardiovascular effects of alpha-2 adrenoceptor agonists, only clinically healthy dogs (American Society of Anesthesiologists [ASA] classes I and II) should be administered Zenalpha®. Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature.

Zenalpha®


(medetomidine and vatinoxan hydrochlorides injection)

An innovative alpha-2 combination drug that improves the sedation experience from start to finish.

Zenalpha® is indicated for use as a sedative and analgesic in dogs to facilitate clinical examinations, clinical procedures, and minor surgical procedures.



TIME TO ONSET
5-15 Minutes



in most cases*

*Field study mean was 14 minutes for time to onset of sedation.

DURATION OF SEDATION
~45 Minutes



in most cases*

*Field study mean was 38 minutes for duration of sedation.

IMPORTANT SAFETY INFORMATION

As with all drugs, side effects may occur. For use in dogs only. Not intended for use in cats. Not for use in humans. Avoid skin, eye or mucosal contact. In case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician. DO NOT DRIVE as sedation, loss of consciousness, and changes in blood pressure may occur. People with cardiovascular disease and pregnant women should exercise special caution to avoid exposure. As with all alpha-2 adrenoceptor agonists, onset of sedation may be delayed or may be inadequate in some dogs. The analgesic effect of Zenalpha will not last longer than the sedative effects. Additional analgesic(s) should be administered as needed. Do not use Zenalpha in dogs with cardiac disease, respiratory disorders, shock, severe debilitation, that have hypoglycemia or are at risk of developing hypoglycemia, or are stressed due to extreme heat, cold or fatigue. Zenalpha should not be administered in the presence of pre-existing hypotension, hypoxia or bradycardia. Due to the pronounced cardiovascular effects of alpha2-adrenoceptor agonists, only clinically healthy dogs (American Society of Anesthesiologists [ASA] classes I and II) should be administered Zenalpha. Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature. Tachycardia may occur in some dogs after recovery from sedation. The following adverse reactions have been reported: diarrhea, muscle tremors and colitis. Refer to the prescribing information for complete details or visit www.dechra-us.com.

sound byte

CHECK-OFF & ECHO NOTES

First, always ask if a Dechra representative has been in contact recently:

Doctor, have you recently been introduced to Zenalpha® (medetomidine and vatinoxan hydrochlorides injection)?

If **Yes**, confirm and discuss benefits.

If **No**, engage/detail the customer as the primary contact.

Confidence

I believe Zenalpha® will become an important tool for increasing procedural efficiency in your clinic and provide less stress for your veterinary team.

Neutral invitation

Let's take a look at some basic information about Zenalpha®...

It's the customer's decision

...so you can decide whether Zenalpha® is a sedative you'll consider using with your canine patients for clinical exams and procedures.